Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:33:18 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



Q:ALNY - ALNYLAM PHARMACEUTICALS INC - http://www.alnylam.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALNY - Q0.3151.57·152.001.2151.80+0.580.424.83,736414152.42  152.57  150.825218.88  141.97510:12:5708:0015 min RT 2¢

Recent Trades - Last 10 of 414
Time ETExPriceChangeVolume
10:12:57Q151.800.58100
10:12:52Q151.750.531
10:12:52Q151.750.5311
10:12:52Q151.7950.5755
10:12:52Q151.7950.57512
10:12:52Q151.7950.57542
10:12:52Q151.7950.57538
10:12:51Q151.56310.34311
10:12:47Q151.720.50100
10:12:36Q151.470.25100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-07 08:00U:ALNYNews ReleaseAlnylam Issues 2023 Corporate Responsibility Report
2024-05-02 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-04-30 07:00U:ALNYNews ReleaseMedison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
2024-04-18 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024-04-07 08:00U:ALNYNews ReleaseAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
2024-03-20 08:00U:ALNYNews ReleaseAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
2024-03-13 07:30U:ALNYNews ReleaseAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
2024-03-05 07:30U:ALNYNews ReleaseAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
2024-02-27 08:30U:ALNYNews ReleaseAlnylam to Webcast Presentations at Upcoming March Investor Conferences
2024-02-15 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
2024-01-29 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
2024-01-09 08:05U:ALNYNews ReleaseAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen ¢ € ™s Association
2024-01-07 18:00U:ALNYNews ReleaseAlnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
2024-01-02 07:30U:ALNYNews ReleaseAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 07:30U:ALNYNews ReleaseAlnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
2023-12-06 08:00U:ALNYNews ReleaseAlnylam to Webcast Virtual R&D Day
2023-11-30 08:00U:ALNYNews ReleaseAlnylam Ranks #1 on Boston Globe ¢ € ™s Top Places to Work List for 2023
2023-11-11 16:00U:ALNYNews ReleaseAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
2023-11-07 08:00U:ALNYNews ReleaseAlnylam to Webcast Presentations at Upcoming November Investor Conferences